Cerebral Glucose Hypometabolism in Neurodegeneration

VIM Protein (Vimentin)

Introduction

Cerebral Glucose Hypometabolism In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>VIM (Vimentin)</td></tr>
<tr><th>Gene</th><td>[VIM](/proteins/vim-protein)</td></tr>
<tr><th>UniProt ID</th><td>[P08670](https://www.uniprot.org/uniprotkb/P08670)</td></tr>
<tr><th>PDB ID</th><td>1GK4, 3KLT, 4YV3</td></tr>
<tr><th>Molecular Weight</th><td>54 kDa (466 amino acids)</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm, intermediate filaments, perinuclear region</td></tr>
<tr><th>Protein Family</th><td>Type III intermediate filament family</td></tr>
<tr><th>Brain Expression</th><td>Neurons, astrocytes, oligodendrocytes, microglia</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Multiple Sclerosis</td></tr>
</table>
</div>

Overview

...

VIM Protein (Vimentin)

Introduction

Cerebral Glucose Hypometabolism In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>VIM (Vimentin)</td></tr>
<tr><th>Gene</th><td>[VIM](/proteins/vim-protein)</td></tr>
<tr><th>UniProt ID</th><td>[P08670](https://www.uniprot.org/uniprotkb/P08670)</td></tr>
<tr><th>PDB ID</th><td>1GK4, 3KLT, 4YV3</td></tr>
<tr><th>Molecular Weight</th><td>54 kDa (466 amino acids)</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm, intermediate filaments, perinuclear region</td></tr>
<tr><th>Protein Family</th><td>Type III intermediate filament family</td></tr>
<tr><th>Brain Expression</th><td>Neurons, astrocytes, oligodendrocytes, microglia</td></tr>
<tr><th>Associated Diseases</th><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Multiple Sclerosis</td></tr>
</table>
</div>

Overview

Vimentin is a type III intermediate filament protein encoded by the [VIM](/proteins/vim-protein) gene that serves as a key structural component of the cytoskeleton in various cell types, including [neurons](/entities/neurons) and glial cells. In the central nervous system, vimentin is expressed predominantly in [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), and neural progenitor cells, with lower expression in mature neurons under normal conditions["@herrmann2007"]. Vimentin plays critical roles in maintaining cellular architecture, facilitating intracellular transport, regulating signal transduction pathways, and responding to cellular stress["@pekny2019"].

The protein is particularly notable for its upregulation in reactive astrocytes (a process termed astrocytosis or glial scarring) in response to neurodegeneration, making it a widely used marker for assessing neuroinflammatory responses in neurodegenerative disease["@shabbir2014"]. Beyond its structural functions, vimentin participates in numerous protein-protein interactions that regulate [apoptosis](/mechanisms/apoptosis), [autophagy](/entities/autophagy), mitochondrial dynamics, and immune responses—all processes central to neurodegeneration["@eriksson2009"].

Structure

Vimentin exhibits the characteristic architecture of type III intermediate filament proteins:

Primary Structure

• Length: 466 amino acids
• Molecular weight: ~54 kDa
• Isoforms: Multiple splice variants exist, including vimentin-v (a shorter variant)

Domain Organization

N-terminal head domain (amino acids 1-96): Non-helical, glycine-rich region containing multiple phosphorylation sites. This domain participates in protein-protein interactions and filament assembly initiation[@snider2011].

Central rod domain (amino acids 97-410): Alpha-helical coiled-coil structure consisting of four conserved helical segments (1A, 1B, 2A, 2B) separated by linker regions (L1, L12, L2). The coiled-coil mediates dimerization and higher-order assembly[@fuchs1994].

C-terminal tail domain (amino acids 411-466): Variable region involved in post-translational modifications and protein interactions. Contains serine/threonine phosphorylation sites that regulate filament dynamics[@inagaki1996].

Quaternary Structure

Vimentin assembles into a hierarchical structure:

• Two polypeptides form a coiled-coil dimer (the basic unit)
• Two dimers associate to form a tetramer (soluble subunit)
• Tetramers assemble into unit-length filaments
• Filaments bundle together to form 10nm intermediate filaments

Post-Translational Modifications

Vimentin undergoes extensive post-translational modifications:

• Phosphorylation: Multiple serine/threonine kinases (PKC, CaMKII, Aurora B) phosphorylate vimentin, regulating filament disassembly during mitosis and stress responses[@goto1998]
• Methylation: Arginine methylation affects protein interactions
• Acetylation: Lysine acetylation influences filament stability
• SUMOylation: SUMO modification affects subcellular localization

Normal Function

Cytoskeletal Architecture

Vimentin provides mechanical support and maintains cellular integrity:

• Forms a dynamic network extending from the nucleus to the plasma membrane
• Coordinates organelle positioning, particularly mitochondria
• Supports axonal and dendritic structure in neurons
• Facilitates cell migration and process extension

Astrocyte Function

In astrocytes, vimentin:

• Partners with [GFAP](/genes/gfap) to form intermediate filament networks
• Supports astrocyte morphology and process stability
• Enables astrocyte migration during development and injury response
• Facilitates calcium wave propagation through the astrocyte network

Neural Development

During development, vimentin:

• Guides neural crest cell migration
• Supports radial glial cell scaffolding for neuronal migration
• Enables process outgrowth in developing neurons
• Facilitates synapse formation and remodeling

Cellular Homeostasis

Vimentin regulates:

• Mitochondrial distribution and quality control: Vimentin cages surround mitochondria, facilitating proper distribution and selective removal of damaged organelles[@tang2019]
• [Autophagy](/mechanisms/autophagy-lysosome-neurodegeneration): Interacts with autophagy receptors to facilitate clearance of protein aggregates
• [Apoptosis](/mechanisms/apoptosis): Modulates caspase activation and apoptotic signaling
• Cell signaling: Serves as scaffold for various signaling pathways (MAPK, PI3K/Akt)

Role in Neurodegenerative Diseases

Alzheimer's Disease

Vimentin pathology in AD is extensive and multifaceted:

Astrocytic Reactivity
Vimentin is dramatically upregulated in reactive astrocytes surrounding [amyloid-beta](/proteins/amyloid-beta) plaques[@kahlson2022]. These vimentin-positive astrocytes exhibit:

• Hypertrophic morphology with enlarged processes
• Increased [GFAP](/entities/gfap) and vimentin co-expression
• Enhanced inflammatory cytokine production

Relationship to Neurofibrillary Tangles

• Vimentin can be incorporated into aberrant filamentous structures
• Cross-linking with [tau protein](/proteins/tau) may stabilize pathological aggregates
• Phosphorylation patterns in vimentin mirror [tau](/proteins/tau) pathology

[Blood-Brain Barrier](/entities/blood-brain-barrier)

• Vimentin in astrocyte end-feet contributes to BBB maintenance
• Disruption of vimentin networks correlates with BBB leakage in AD
• Altered vimentin affects [astrocyte](/cell-types/astrocytes) uptake of [Aβ](/proteins/amyloid-beta)

Parkinson's Disease

Microglial Activation

• Vimentin is upregulated in activated [microglia](/cell-types/microglia) in the substantia nigra
• Vimentin-positive [microglia](/cell-types/microglia) cluster around dopaminergic neurons
• Correlates with disease severity and progression

[Alpha-Synuclein](/proteins/alpha-synuclein) Connection

• Vimentin may facilitate [alpha-synuclein](/proteins/alpha-synuclein) aggregation
• Interacts with Lewy body structures
• May influence prion-like spread of [α-synuclein](/proteins/alpha-synuclein) pathology

Neuroinflammation

• Vimentin released from damaged cells acts as DAMP (damage-associated molecular pattern)
• Triggers [TLR4](/entities/tlr4)-mediated inflammatory responses
• Amplifies microglial activation in a feed-forward manner

Amyotrophic Lateral Sclerosis (ALS)

Astrocytic Dysfunction

• Upregulated in astrocytes in ALS models and patients
• Contributes to non-cell autonomous neuronal death
• Vimentin-positive astrocytes show impaired glutamate uptake

Protein Aggregate Clearance

• Vimentin interacts with [TDP-43](/proteins/tdp-43) aggregates (pathological hallmark of ALS)
• May sequester clearance machinery
• Affects autophagy-lysosomal pathway function

Multiple Sclerosis

Glial Scarring

• Vimentin is a major component of the glial scar
• Upregulated in reactive astrocytes around demyelinating lesions
• Both beneficial (containing inflammation) and detrimental (inhibiting repair) roles

Oligodendrocyte Precursor Cells

• Vimentin expressed in OPCs during migration
• Necessary for proper OPC differentiation
• Dysregulation may impair remyelination

Therapeutic Implications

Biomarker Potential

Vimentin shows promise as a biomarker:

• CSF biomarker: Vimentin levels elevated in CSF of AD and PD patients[@olsson2016]
• Blood biomarker: Peripheral blood monocyte vimentin expression correlates with disease state
• Imaging target: PET ligands targeting vimentin-reactive astrocytes under development

Therapeutic Targets

Reducing Vimentin Expression

• Antisense oligonucleotides targeting VIM reduce astrocyte reactivity
• CRISPR-based approaches show promise in preclinical models
• Must balance beneficial (anti-inflammatory) and detrimental (support deficits) effects

Modifying Post-Translational Modifications

• Kinase inhibitors (e.g., PKC inhibitors) reduce vimentin phosphorylation
• May decrease astrocyte reactivity and neuroinflammation

Blocking Vimentin Release

• Inhibition of vimentin secretion as DAMP
• Neutralizing antibodies against extracellular vimentin
• Reduces microglial activation

Drug Development

Several strategies are being explored:

• Small molecule inhibitors: Targeting vimentin polymerization
• Natural compounds: Curcumin and other polyphenols affect vimentin dynamics
• Gene therapy: AAV-mediated VIM knockdown in astrocytes

Interactions and Pathways

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|----------------------|
| [GFAP](/genes/gfap) | Heterodimer formation | Astrocyte IF network |
| [Tau](/proteins/tau) | Co-aggregation | NFT formation |
| [α-Synuclein](/proteins/alpha-synuclein) | Binding | Lewy body formation |
| [TDP-43](/proteins/tdp-43) | Co-aggregation | ALS pathology |
| Beclin-1 | Autophagy regulation | Mitophagy |
| Parkin | Mitochondrial quality control | PD pathogenesis |

Signaling Pathways

• MAPK/ERK pathway: Vimentin phosphorylation regulates activation
• PI3K/Akt: Vimentin scaffold enables downstream signaling
• [NF-κB](/entities/nf-kb): Vimentin supports inflammatory gene expression
• JNK/c-Jun: Stress-activated kinase phosphorylates vimentin

Research Techniques

Detection Methods

• Immunohistochemistry: Antibodies against vimentin (clone V9) widely used
• Western blot: 57 kDa band detected under reducing conditions
• ELISA: Quantifies soluble vimentin in biofluids
• PET imaging: Novel tracers for reactive astrocytes

Model Systems

• Vimentin knockout mice: Viable and fertile, but show wound healing deficits
• Transgenic models: Human VIM overexpression under astrocyte promoters
• iPSC-derived astrocytes: Patient-specific models for disease modeling

Background

The study of Cerebral Glucose Hypometabolism In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• VIM Gene
• [GFAP Protein](/proteins/gfap-protein)
• [Astrocytes](/cell-types/astrocytes)
• [Microglia](/cell-types/microglia)
• Intermediate Filaments
• [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-disease-mechanisms)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
• [Neuroinflammation](/mechanisms/neuroinflammation-pathway)
• Glial Scarring

Pathway Diagram

The following diagram shows the key molecular relationships involving Cerebral Glucose Hypometabolism in Neurodegeneration discovered through SciDEX knowledge graph analysis: